These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11322265)

  • 21. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
    Opravil M; Hirschel B; Lazzarin A; Furrer H; Chave JP; Yerly S; Bisset LR; Fischer M; Vernazza P; Bernasconi E; Battegay M; Ledergerber B; Günthard H; Howe C; Weber R; Perrin L;
    J Infect Dis; 2002 May; 185(9):1251-60. PubMed ID: 12001042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
    Dykes C; Najjar J; Bosch RJ; Wantman M; Furtado M; Hart S; Hammer SM; Demeter LM
    J Infect Dis; 2004 Mar; 189(6):1091-6. PubMed ID: 14999613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy.
    Riva E; Antonelli G; Solmone MC; Turriziani O; Narciso P; Tozzi V; Dianzani F
    J Biol Regul Homeost Agents; 2000; 14(1):1-3. PubMed ID: 10763882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
    Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F
    Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
    Parkin NT; Lie YS; Hellmann N; Markowitz M; Bonhoeffer S; Ho DD; Petropoulos CJ
    J Infect Dis; 1999 Sep; 180(3):865-70. PubMed ID: 10438382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients.
    Wainberg MA; Lewis L; Salomon H; Gu Z; Keller A; Cammack N; Goldsmith J; Church J; Spira B; Wheeler S; Pizzo P
    Antivir Ther; 1996 Apr; 1(2):98-104. PubMed ID: 11321185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.
    Rusconi S; La Seta Catamancio S; Citterio P; Bulgheroni E; Kurtagic S; Galazzi M; Croce F; Moroni M; Galli M
    Antivir Ther; 2001 Mar; 6(1):41-6. PubMed ID: 11417760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance.
    Katzenstein TL; Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    Antivir Ther; 1996 Dec; 1(4):246-54. PubMed ID: 11324827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
    Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
    Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.